{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:12:56Z","timestamp":1792141976296,"version":"4.4.0"},"reference-count":50,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Sirolimus is an effective agent used in graft-versus-host disease (GVHD) prophylaxis after allogeneic transplantation. It also has antiproliferative effects on vascular endothelium when used to coat coronary artery stents. We noted an excess of veno-occlusive disease (VOD) in a clinical trial, and retrospectively reviewed the records of 488 patients to determine the association between sirolimus and VOD. When used with cyclophosphamide\/total body irradiation (Cy\/TBI) conditioning, sirolimus is associated with an increased incidence of VOD (OR 2.35, P = .005). The concomitant use of methotrexate further increased this rate (OR 3.23, P &lt; .001), while sirolimus without methotrexate was not associated with an increased risk of VOD (OR 1.55, P = .33). Mortality after VOD diagnosis was unaffected, and overall treatment-related mortality was lowest when sirolimus was used without methotrexate. Similar findings were noted in matched, related, and unrelated as well as mismatched donor subgroups. When used with busulfan-based conditioning, sirolimus use was associated with an even higher rate of VOD (OR 8.8, P = .008). Our findings suggest that sirolimus use is associated with VOD after TBI-based transplantation when used with methotrexate after transplantation. Sirolimus-based GVHD prophylaxis without methotrexate is associated with the greatest overall survival. Myeloablative doses of busulfan should not be used with sirolimus-based immunosuppression.<\/jats:p>","DOI":"10.1182\/blood-2008-07-169342","type":"journal-article","created":{"date-parts":[[2008,9,5]],"date-time":"2008-09-05T21:24:51Z","timestamp":1220649891000},"page":"4425-4431","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":131,"title":["Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation"],"prefix":"10.1182","volume":"112","author":[{"given":"Corey","family":"Cutler","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Blood and Marrow Transplant Clinical Trials Network, Rockville, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Stevenson","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haesook T.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Richardson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent T.","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Linden","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Revta","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Ebert","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Warren","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung","family":"Choi","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Clinical Trials Network, Rockville, MD;"},{"name":"University of Michigan Medical Center, Ann Arbor;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Koreth","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Alyea","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly","family":"Carter","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Clinical Trials Network, Rockville, MD;"},{"name":"EMMES Corporation, Rockville, MD; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Horowitz","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Clinical Trials Network, Rockville, MD;"},{"name":"The Center for International Blood and Marrow Transplant Research, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph H.","family":"Antin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Blood and Marrow Transplant Clinical Trials Network, Rockville, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Soiffer","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Blood and Marrow Transplant Clinical Trials Network, Rockville, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111714510320200_B1","doi-asserted-by":"crossref","first-page":"201S","DOI":"10.1016\/S0041-1345(03)00231-8","article-title":"Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation.","volume":"35","author":"MacDonald","year":"2003","journal-title":"Transplant Proc"},{"key":"2019111714510320200_B2","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/S0041-1345(03)00234-3","article-title":"Sirolimus in liver transplantation.","volume":"35","author":"Trotter","year":"2003","journal-title":"Transplant Proc"},{"key":"2019111714510320200_B3","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/01.TP.0000101495.22734.07","article-title":"A randomized long-term trial of tacrolimus\/sirolimus versus tacrolimus\/mycophenolate mofetil versus cyclosporine (NEORAL)\/sirolimus in renal transplantation, II: survival, function, and protocol compliance at 1 year.","volume":"77","author":"Ciancio","year":"2004","journal-title":"Transplantation"},{"key":"2019111714510320200_B4","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/00041552-200211000-00006","article-title":"Sirolimus (Rapamune) in renal transplantation.","volume":"11","author":"Johnson","year":"2002","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2019111714510320200_B5","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1182\/blood-2003-02-0489","article-title":"Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation.","volume":"102","author":"Antin","year":"2003","journal-title":"Blood"},{"key":"2019111714510320200_B6","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1182\/blood-2006-09-046219","article-title":"Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation.","volume":"109","author":"Cutler","year":"2007","journal-title":"Blood"},{"key":"2019111714510320200_B7","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1182\/blood-2007-01-069294","article-title":"Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis.","volume":"110","author":"Marty","year":"2007","journal-title":"Blood"},{"key":"2019111714510320200_B8","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.bbmt.2005.02.006","article-title":"Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens.","volume":"11","author":"Cutler","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111714510320200_B9","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1056\/NEJMp038141","article-title":"Sirolimus for the prevention of in-stent restenosis in a coronary artery.","volume":"349","author":"Marks","year":"2003","journal-title":"N Engl J Med"},{"key":"2019111714510320200_B10","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1161\/01.CIR.0000155612.47040.17","article-title":"Potent inhibitory effect of sirolimus on circulating vascular progenitor cells.","volume":"111","author":"Fukuda","year":"2005","journal-title":"Circulation"},{"key":"2019111714510320200_B11","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1096\/fj.01-0658com","article-title":"Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling.","volume":"16","author":"Humar","year":"2002","journal-title":"FASEB J"},{"key":"2019111714510320200_B12","doi-asserted-by":"crossref","first-page":"231S","DOI":"10.1016\/S0041-1345(03)00243-4","article-title":"Rapamycin: signaling in vascular smooth muscle.","volume":"35","author":"Marks","year":"2003","journal-title":"Transplant Proc"},{"key":"2019111714510320200_B13","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.bbmt.2005.04.007","article-title":"Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation.","volume":"11","author":"Cutler","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111714510320200_B14"},{"key":"2019111714510320200_B15","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/jlts.2003.50079","article-title":"Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications.","volume":"9","author":"Dunkelberg","year":"2003","journal-title":"Liver Transpl"},{"key":"2019111714510320200_B16","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1053\/jlts.2001.26510","article-title":"Orthotopic liver transplantation using low-dose tacrolimus and sirolimus.","volume":"7","author":"McAlister","year":"2001","journal-title":"Liver Transpl"},{"key":"2019111714510320200_B17","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/00007890-199902270-00002","article-title":"Sirolimus: a potent new immunosuppressant for liver transplantation.","volume":"67","author":"Watson","year":"1999","journal-title":"Transplantation"},{"key":"2019111714510320200_B18","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/00007890-199904150-00017","article-title":"Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group.","volume":"67","author":"Groth","year":"1999","journal-title":"Transplantation"},{"key":"2019111714510320200_B19","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/sj.bmt.1703047","article-title":"Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation.","volume":"27","author":"Copelan","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"2019111714510320200_B20","first-page":"225","article-title":"Association of busulfan area under the curve with veno-occlusive disease following BMT.","volume":"17","author":"Dix","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"2019111714510320200_B21","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1182\/blood.V83.9.2723.2723","article-title":"A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group.","volume":"83","author":"Ringden","year":"1994","journal-title":"Blood"},{"key":"2019111714510320200_B22","first-page":"75","article-title":"Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia.","volume":"17","author":"Rozman","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"2019111714510320200_B23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/sj.bmt.1705899","article-title":"Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies.","volume":"41","author":"Ho","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"2019111714510320200_B24","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","article-title":"Venoocclusive disease of the liver following bone marrow transplantation.","volume":"44","author":"Jones","year":"1987","journal-title":"Transplantation"},{"key":"2019111714510320200_B25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"2019111714510320200_B26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2307\/2344317","article-title":"Asymptotically efficient rank invariant procedures.","volume":"135A","author":"Peto","year":"1972","journal-title":"Journal of the Royal Statistical Society"},{"key":"2019111714510320200_B27","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk.","volume":"16","author":"Gray","year":"1988","journal-title":"Annals of Statistics"},{"key":"2019111714510320200_B28","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk.","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"2019111714510320200_B29","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1253\/circj.71.220","article-title":"Impaired endothelial vasomotor function after sirolimus-eluting stent implantation.","volume":"71","author":"Fuke","year":"2007","journal-title":"Circ J"},{"key":"2019111714510320200_B30","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.atherosclerosis.2005.12.031","article-title":"Sirolimus accelerates senescence of endothelial progenitor cells through telomerase inactivation.","volume":"189","author":"Imanishi","year":"2006","journal-title":"Atherosclerosis"},{"key":"2019111714510320200_B31","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/S0016-5085(99)70406-3","article-title":"Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis.","volume":"117","author":"Zhu","year":"1999","journal-title":"Gastroenterology"},{"key":"2019111714510320200_B32","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/01.fjc.0000248233.22570.8b","article-title":"Effects of tacrolimus or sirolimus on proliferation of vascular smooth muscle and endothelial cells.","volume":"48","author":"Matter","year":"2006","journal-title":"J Cardiovasc Pharmacol"},{"key":"2019111714510320200_B33","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1111\/j.1600-6143.2005.01047.x","article-title":"Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys.","volume":"5","author":"Sartelet","year":"2005","journal-title":"Am J Transplant"},{"key":"2019111714510320200_B34","doi-asserted-by":"crossref","first-page":"209a","DOI":"10.1182\/blood.V104.11.730.730","article-title":"Sirolimus, tacrolimus and reduced-dose methotrexate as graft versus host disease (GVHD) prophylaxis after non-myeloablative stem cell transplantation:low incidence of acute GVHD compared with tacrolius\/methotrexate or cyclosporine\/prednisone.","volume":"104","author":"Alyea","year":"2004","journal-title":"Blood"},{"key":"2019111714510320200_B35","doi-asserted-by":"crossref","first-page":"895a","DOI":"10.1182\/blood.V110.11.3046.3046","article-title":"Tacrolimus and sirolimus without methotrexate as acute GVHD prophylaxis after matched related donor reduced intensity conditioning (RIC) stem cell transplantation (SCT).","volume":"110","author":"Ho","year":"2007","journal-title":"Blood"},{"key":"2019111714510320200_B36","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/sj.bjc.6603097","article-title":"High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy.","volume":"94","author":"de Jonge","year":"2006","journal-title":"Br J Cancer"},{"key":"2019111714510320200_B37","first-page":"817a","article-title":"Graft versus host disease prophylaxis with everolimus and tacrolimus in patients with myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML) receiving allogeneic peripheral blood stem cell transplantation (PBSCT).","volume":"108","author":"Platzbecker","year":"2006","journal-title":"ASH Annual Meeting Abstracts"},{"key":"2019111714510320200_B38","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cca.2005.12.011","article-title":"Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan.","volume":"368","author":"Kusama","year":"2006","journal-title":"Clin Chim Acta"},{"key":"2019111714510320200_B39","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1034\/j.1600-0773.2001.d01-147.x","article-title":"Cholestasis and regulation of genes related to drug metabolism and biliary transport in rat liver following treatment with cyclosporine A and sirolimus (Rapamycin).","volume":"89","author":"Bramow","year":"2001","journal-title":"Pharmacol Toxicol"},{"key":"2019111714510320200_B40","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00277-004-0982-4","article-title":"Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation.","volume":"84","author":"Lee","year":"2005","journal-title":"Ann Hematol"},{"key":"2019111714510320200_B41","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1053\/bbmt.2002.v8.pm12374454","article-title":"Intravenous versus oral busulfan as part of a busulfan\/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality.","volume":"8","author":"Kashyap","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111714510320200_B42","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.bbmt.2007.12.062","article-title":"Inclusion of sirolimus in the GVHD prophylaxis regimen is associated with improved survival in patients with lymphoma undergoing allogeneic transplantation.","volume":"14","author":"Armand","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111714510320200_B43","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1046\/j.1365-2141.2002.03748.x","article-title":"Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide.","volume":"118","author":"Lee","year":"2002","journal-title":"Br J Haematol"},{"key":"2019111714510320200_B44","first-page":"383","article-title":"Increased plasma level of vascular endothelial glycoprotein thrombomodulin as an early indicator of endothelial damage in bone marrow transplantation.","volume":"18","author":"Testa","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"2019111714510320200_B45","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/01.tp.0000296831.91303.9a","article-title":"Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy.","volume":"85","author":"Pontrelli","year":"2008","journal-title":"Transplantation"},{"key":"2019111714510320200_B46","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.bmt.1704329","article-title":"Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention.","volume":"33","author":"Corbacioglu","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"2019111714510320200_B47","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/blood-2002-04-1216","article-title":"Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"key":"2019111714510320200_B48","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.bbmt.2004.01.002","article-title":"Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation.","volume":"10","author":"Chalandon","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111714510320200_B49","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/pbc.21425","article-title":"Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children.","volume":"50","author":"Qureshi","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"2019111714510320200_B50","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1182\/blood-2003-01-0255","article-title":"Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation.","volume":"102","author":"Wadleigh","year":"2003","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/112\/12\/4425\/1482218\/zh802408004425.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/112\/12\/4425\/1482218\/zh802408004425.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T14:51:22Z","timestamp":1574002282000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/112\/12\/4425\/24462\/Sirolimus-is-associated-with-venoocclusive-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,1]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2008,12,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2008-07-169342","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,1]]}}}